NCT06705335 Convertases and Pancreatic Cancer: Cohort of Patients Treated for Pancreatic Adenocarcinoma

Trial Parameters

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This is a prospective, single-centre, observational study. The analysis of samples of pancreatic tumours and/or metastases taken during biopsy or surgery will lead to the determination of the level of expression of convertases in patients with pancreatic cancer and could be used as an additional prognostic means reinforcing those currently used.

Eligibility Criteria

Inclusion Criteria: 1. Age ≥ 18 years. 2. Pancreatic adenocarcinoma (suspected on radiological assessment or histologically proven): 1. Indication for biopsy of metastasis(es) performed as part of standard care for patients who already have a histologically confirmed diagnosis of pancreatic cancer. 2. Indication for pancreatic surgery or metastasis(es) carried out as part of standard care for patients with a suspicion of pancreatic cancer on radiological assessment or who already have a confirmed histological diagnosis of pancreatic cancer. 3. Whatever the stage of the disease. 4. Whatever the type of treatment proposed (systemic, surgery, radiotherapy, etc.). 5. Patient who has never received systemic treatment or advanced radiotherapy. 6. WHO 0-1-2. 7. Life expectancy \> 3 months. 8. Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research). 9. Patient affiliated to a s

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.